RxDoctor Payments Data

Derek Kuhl, MD

Ophthalmology · Bryan, TXNPI 1629074844

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 50 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$391
  • Genentech USA, Inc.$273
  • Regeneron Healthcare Solutions, Inc.$212
  • Optos, Inc.$137
  • Sun Pharmaceutical Industries Inc.$111
  • Biogen$106
  • plus $120 from 4 others

What the payments were for

  • Food & beverage$1,17887%
  • Education$363%
  • Entertainment$13710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,350 in reported general payments places this provider in the 40th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$1,690,770
Medicare patients
794
Services billed
12,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine41$19,827
ProlensaBromfenac Sodium36$15,670
MieboPerfluorohexyloctane/Pf15$13,563
Bromfenac Sodium65$12,675
Prednisolone Acetate194$10,423
Loteprednol Etabonate38$6,513
RhopressaNetarsudil Mesylate18$5,345
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$3,481
Lotemax SmLoteprednol Etabonate11$2,678
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat124$2,072
Timolol Maleate148$1,709
Difluprednate15$1,413
Latanoprost121$1,133
Ofloxacin99$1,054
Brimonidine Tartrate89$892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm$31$24,86285 claims
Bausch & Lomb Americas Inc.Miebo$50$13,56315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →